Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Financial Officer | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,208 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 61 · Balance 123,208 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | Direct | 119,216 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 3,992 · Balance 119,216 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: Includes 43,650 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: Includes 43,650 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2023 Filed Oct 23, 2023 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,137 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-23-000313 · form4.xml · derivative · entry 4 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,137 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,387 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001610717-23-000313 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,814 Underlying: Common Stock · 19,387 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 5,137 | $4.09 | $21,010.33 |
DisclosureSEC source: 0001610717-23-000313 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 40,800 restricted stock units. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 19,387 | $2.68 | $51,957.16 |
DisclosureSEC source: 0001610717-23-000313 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 40,800 restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,427 | $31.31 | $44,680.23 |
DisclosureSEC source: 0001610717-23-000292 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,667 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $31.101 to $31.3108, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 40,800 restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001610717-23-000259 · form4.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,201 Underlying: Common Stock · 20,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 20,000 | $35.05 | $701,092.00 |
DisclosureSEC source: 0001610717-23-000259 · form4.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,094 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 44,276 restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 20,000 | $2.68 | $53,600.00 |
DisclosureSEC source: 0001610717-23-000259 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023. F2 · balance_after: Includes 44,276 restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,249 | $24.89 | $31,088.86 |
DisclosureSEC source: 0001610717-23-000193 · form4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,094 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 1,110 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. F3 · balance_after: Includes 44,276 RSUs. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:33 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 665 | $21.78 | $14,483.70 |
DisclosureSEC source: 0000899243-23-009376 · doc4.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,233 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.4075 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 47,750 RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 93,100 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001567619-23-004356 · doc1.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,100 Underlying: Common Stock · 93,100 shares Expires 2033-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 26,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004356 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,898 F1 · balance_after: Includes 49,563 restricted stock units. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 658 | $22.94 | $15,094.85 |
DisclosureSEC source: 0001567619-22-021930 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,298 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.4716 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 22,964 RSUs. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 449 | $19.04 | $8,550.13 |
DisclosureSEC source: 0001567619-22-017689 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,956 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.98 to $19.0337, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 24,776 RSUs. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0001567619-22-016989 · doc1.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-08-31 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-016989 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,405 F1 · balance_after: Includes 25,964 restricted stock units. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 406 | $17.75 | $7,206.30 |
DisclosureSEC source: 0001567619-22-013250 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,405 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 936 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022. F3 · balance_after: Includes 15,964 RSUs. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 00:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 159 | $18.62 | $2,959.98 |
DisclosureSEC source: 0001567619-22-007323 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,875 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.32 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 17,151 RSUs. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 40,600 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001567619-22-006234 · doc1.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,600 Underlying: Common Stock · 40,600 shares Expires 2032-02-29 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 11,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006234 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,034 F1 · balance_after: Includes 17,613 Restricted Stock Units. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:34 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 170 | $24.41 | $4,149.70 |
DisclosureSEC source: 0001567619-21-022406 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,434 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 412 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2021. F3 · balance_after: Includes 6,013 RSUs. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 23:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 166 | $30.02 | $4,983.32 |
DisclosureSEC source: 0001567619-21-017417 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,192 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 6,475 RSUs. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 160 | $34.12 | $5,459.86 |
DisclosureSEC source: 0001567619-21-012487 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,358 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $33.66 to $34.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 614 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021. F4 · balance_after: Includes 6,938 RSUs. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:42 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 25,900 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001567619-21-005847 · doc1.xml · derivative · entry 2 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,900 Underlying: Common Stock · 25,900 shares Expires 2031-03-03 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:42 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 7,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005847 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,904 F1 · balance_after: Includes 7,400 Restricted Stock Units. F2 · balance_after: Includes 504 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 23:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017887 · doc1.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,201 Underlying: Common Stock · 10,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vest on the first anniversary measured from August 16, 2018 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 23:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $44.00 | $440,000.00 |
DisclosureSEC source: 0001567619-20-017887 · doc1.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 23:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $2.68 | $26,800.00 |
DisclosureSEC source: 0001567619-20-017887 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017693 · doc1.xml · derivative · entry 3 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,201 Underlying: Common Stock · 10,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vest on the first anniversary measured from August 16, 2018 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001567619-20-017693 · doc1.xml · nonDerivative · entry 2 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 10,000 | $2.68 | $26,800.00 |
DisclosureSEC source: 0001567619-20-017693 · doc1.xml · nonDerivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:21 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 17,467 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004010 · doc1.xml · derivative · entry 1 Anders Jack · CIK 0001800668 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,467 Underlying: Common Stock · 17,467 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.